Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Krasner

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
Cancer Chemotherapy and Pharmacology|February 10, 2022
A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignanciesSusana M Campos, Suzanne Berlin, Carolyn N Krasner, et al.
British Journal of Cancer|November 1, 1989
A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinomaJ J Keating, P J Johnson, A M Cochrane, et al.
Gynecologic Oncology|July 7, 2012
Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD aloneCarolyn N Krasner, Andres Poveda, Thomas J Herzog, et al.
Gynecologic Oncology|November 20, 2009
Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumorsMaria R Roche, Pandora J Rudd, Carolyn N Krasner, et al.
Cancer|July 16, 2016
Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancerMarcela G Del Carmen, Jeff G Supko, Nora K Horick, et al.
Gynecologic Oncology|July 4, 2012
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulvaN S Horowitz, A B Olawaiye, D R Borger, et al.
International Journal of Clinical Oncology|April 21, 2010
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancerSusana M Campos, Suzanne T Berlin, Leroy M Parker, et al.
Medical Oncology (Northwood, London, England)|February 12, 2013
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trialsJosé María del Campo, Cristiana Sessa, Carolyn N Krasner, et al.
Journal of the National Cancer Institute|April 19, 2023
Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitorsShruti Gupta, Paul E Hanna, Tianqi Ouyang, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 2012
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysisBradley J Monk, Thomas J Herzog, Stanley B Kaye, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
Cancer Chemotherapy and Pharmacology|February 10, 2022
A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignanciesSusana M Campos, Suzanne Berlin, Carolyn N Krasner, et al.
British Journal of Cancer|November 1, 1989
A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinomaJ J Keating, P J Johnson, A M Cochrane, et al.
Gynecologic Oncology|July 7, 2012
Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD aloneCarolyn N Krasner, Andres Poveda, Thomas J Herzog, et al.
Gynecologic Oncology|November 20, 2009
Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumorsMaria R Roche, Pandora J Rudd, Carolyn N Krasner, et al.
Cancer|July 16, 2016
Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancerMarcela G Del Carmen, Jeff G Supko, Nora K Horick, et al.
Gynecologic Oncology|July 4, 2012
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulvaN S Horowitz, A B Olawaiye, D R Borger, et al.
International Journal of Clinical Oncology|April 21, 2010
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancerSusana M Campos, Suzanne T Berlin, Leroy M Parker, et al.
Medical Oncology (Northwood, London, England)|February 12, 2013
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trialsJosé María del Campo, Cristiana Sessa, Carolyn N Krasner, et al.
Journal of the National Cancer Institute|April 19, 2023
Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitorsShruti Gupta, Paul E Hanna, Tianqi Ouyang, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 2012
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysisBradley J Monk, Thomas J Herzog, Stanley B Kaye, et al.
Pageof 11